Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

For This Patient, I Suggest Medical Management and Risk-Factor Reduction Alone (What Have COURAGE and FAME Taught Us?)

Presenter: John D. Puskas, Michael E. Farkouh

October 14, 2015

News Conference News TCT 2015

TCT Remembers Liliana Grinfeld, MD, PhD

October 14, 2015

News Conference News TCT 2015

Trial Results Often Struggle to Keep Pace With Evolving Technology

Nicole Lou

October 13, 2015

Presentation TCT 2015

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Clinicians Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Ajay J. Kirtane

October 12, 2015

Presentation TCT 2015

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Guideline Perspective

Presenter: Bernard J. Gersh, William S. Weintraub, Patrick T. O'Gara

October 12, 2015

Presentation TCT 2015

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Sripal Bangalore

October 11, 2015

Presentation TCT 2013

On the PROSPECT of Reconciling COURAGE and FAME

Presenter: Jagat Narula

October 30, 2013

News Conference News TCT 2013

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

October 30, 2013

News Conference News TCT 2013

ABSORB III and IV Trials Aim to Prove Superiority of BVS

October 28, 2013

News Conference News TCT 2012

TCT Career Achievement Award Goes to CV Pathologist Renu Virmani, MD

October 26, 2012

News Conference News TCT 2012

Paradigm Shift from Ischemia to Vulnerable Plaque Needed to Prevent Sudden Coronary Death

October 24, 2012

Presentation TCT 2012

Are COURAGE and FAME Irrelevant (or Less Relevant) with Current Generation DES?

Presenter: Dean Kereiakes

October 22, 2012

News Conference News TCT 2012

COURAGE, FAME: Revascularization More Effective Than OMT

October 22, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Advertisement

My Takeaways From TCT 2015

For This Patient, I Suggest Medical Management and Risk-Factor Reduction Alone (What Have COURAGE and FAME Taught Us?)

TCT Remembers Liliana Grinfeld, MD, PhD

Trial Results Often Struggle to Keep Pace With Evolving Technology

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Clinicians Perspective

HOT TOPIC 3: How Should Trials Be Interpreted When Technology Has Moved Faster Than the Results? FOCUS on SYNTAX, COURAGE, and FREEDOM Guideline Perspective

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

On the PROSPECT of Reconciling COURAGE and FAME

SMART-CASE: Conservative Revascularization Noninferior to Aggressive Approach

ABSORB III and IV Trials Aim to Prove Superiority of BVS

TCT Career Achievement Award Goes to CV Pathologist Renu Virmani, MD

Paradigm Shift from Ischemia to Vulnerable Plaque Needed to Prevent Sudden Coronary Death

Are COURAGE and FAME Irrelevant (or Less Relevant) with Current Generation DES?

COURAGE, FAME: Revascularization More Effective Than OMT

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content